【环球财经】埃及投资1.5亿美元建设疫苗工厂

Core Insights - Egypt is commencing the construction of a large vaccine and biopharmaceutical factory in the Sukhna Industrial Zone, with a total investment of $150 million [1] - The GENNVAX project will cover an area of 50,000 square meters and, upon completion, will be the largest integrated vaccine production facility in Egypt, capable of producing 29 types of vaccines and serums [1] - The factory is expected to create between 500 to 700 direct jobs and have an annual production capacity of 270 million doses [1] Company Overview - GENNVAX is an Egyptian biopharmaceutical company that is part of El Daba Holding Group, which was established in 1957 [1] - The project aligns with the localization strategy of the Suez Canal Economic Zone, aiming to reduce reliance on imports and promote local development in key industries, particularly healthcare and pharmaceuticals [1] Production Capacity and Market Impact - The initial annual production capacity of GENNVAX is projected to be 270 million doses, while Egypt's annual vaccine consumption is approximately 70 to 80 million doses [1] - This indicates that Egypt could potentially export around 200 million doses of vaccines annually, positioning the country as a regional vaccine production hub [1] - GENNVAX has signed 29 technology transfer agreements for vaccine production, emphasizing genuine local manufacturing rather than mere filling or agency work [1]